About the Authors
- Rolando Herrero
-
* E-mail: herreror@iarc.fr
Affiliation Prevention and Implementation Group, International Agency for Research on Cancer, Lyon, France
- Wim Quint
-
Affiliation DDL Diagnostic Laboratory, Rijswijk, The Netherlands
- Allan Hildesheim
-
Affiliation Division of Cancer Epidemiology and Genetics, National Cancer Institute, Bethesda, Maryland, United States of America
- Paula Gonzalez
-
Affiliation Proyecto Epidemiológico Guanacaste, Fundación INCIENSA, Guanacaste, Costa Rica
- Linda Struijk
-
Affiliation DDL Diagnostic Laboratory, Rijswijk, The Netherlands
- Hormuzd A. Katki
-
Affiliation Division of Cancer Epidemiology and Genetics, National Cancer Institute, Bethesda, Maryland, United States of America
- Carolina Porras
-
Affiliation Proyecto Epidemiológico Guanacaste, Fundación INCIENSA, Guanacaste, Costa Rica
- Mark Schiffman
-
Affiliation Division of Cancer Epidemiology and Genetics, National Cancer Institute, Bethesda, Maryland, United States of America
- Ana Cecilia Rodriguez
-
Affiliation Proyecto Epidemiológico Guanacaste, Fundación INCIENSA, Guanacaste, Costa Rica
- Diane Solomon
-
Affiliation Division of Cancer Prevention, National Cancer Institute, Bethesda, Maryland, United States of America
- Silvia Jimenez
-
Affiliation Proyecto Epidemiológico Guanacaste, Fundación INCIENSA, Guanacaste, Costa Rica
- John T. Schiller
-
Affiliation Laboratory of Cellular Oncology, National Cancer Institute, Bethesda, Maryland, United States of America
- Douglas R. Lowy
-
Affiliation Laboratory of Cellular Oncology, National Cancer Institute, Bethesda, Maryland, United States of America
- Leen-Jan van Doorn
-
Affiliation DDL Diagnostic Laboratory, Rijswijk, The Netherlands
- Sholom Wacholder
-
Affiliation Division of Cancer Epidemiology and Genetics, National Cancer Institute, Bethesda, Maryland, United States of America
- Aimée R. Kreimer
-
Affiliation Division of Cancer Epidemiology and Genetics, National Cancer Institute, Bethesda, Maryland, United States of America
- for the CVT Vaccine Group
-
¶¶Membership of the CVT Vaccine Group is provided in the Acknowledgments
Competing Interests
JTS and DRL report that they are named inventors on US Government-owned HPV vaccine patents (US 5,437,951; US 5,709,996; US 5,716,620; US 5,744,142; US 5,756,284; US 5,871,998; US 5,985,610; US 7,220,419; and US 7,361,356: “Self-assembling recombinant papillomavirus capsid proteins”) that are licensed to GlaxoSmithKline and Merck and for which the National Cancer Institute receives licensing fees. They are entitled to limited royalties as specified by federal law. The following authors: Wim Quint, Leen-Jan van Doorn and Linda Struijk are employed by the commercial company DDL Diagnostic Laboratory, Rijswijk, The Netherlands. Vaccine was provided for our trial by GlaxoSmithKline Biologicals (GSK), under a Clinical Trials Agreement with the National Cancer Institute. GSK also provided support for aspects of the trial associated with regulatory submission needs of the company under FDA BB-IND 7920. The other authors declare that they have no conflicts of interest. This does not alter the authors’ adherence to all the PLOS ONE policies on sharing data and materials.
Author Contributions
Conceived and designed the experiments: RH AH MS ACR DS JTS DRL SW. Performed the experiments: RH WQ AH PG LS HAK CP MS ACR SJ LJVD. Analyzed the data: RH AH PG HAK MS SW ARK. Contributed reagents/materials/analysis tools: WQ HAK LJVD LS. Wrote the paper: RH AH ARK SW MS DS PG.